All In Biotech

Drug Trial Radar · NCT05205330

Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers

An Open-label, Single-arm, Phase Ib/IIa Trial to Evaluate the Safety and Efficacy of the EP4 Receptor Antagonist Vorbipiprant (CR6086) in Combination With the PD-1 Inhibitor Balstilimab (AGEN2034), in Patients With Pretreated Mismatch-repair-proficient and Microsatellite Stable Metastatic Colorectal Cancer, and Other Metastatic GI Cancers.

Last checked: Nov 19, 2026Latest source record: Oct 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

107

Planned (sponsor's estimate)

Start

Nov 23, 2021

Primary completion

Dec 2026

Study completion Jun 2027

Sponsor

Lead sponsor
Rottapharm BiotechIndustry
Sponsor type
Industry
Collaborators
Agenus Inc.
First posted
Jan 25, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase Ib/IIa study comprises a Main Study and a Study Extension. The Main Study has been designed according to a 3+3 Dose Escalation/dose Expansion design in refractory pMMR-MSS mCRC patients. The fixed-dose Expansion phase will be conducted at the recommended dose for expansion (RDE), with the purpose of generating additional and more robust safety and efficacy data. 27 patients are predicted in the Dose Escalation phase and 52 in the Expansion phase, respectively. The Study Extension explores in other metastatic GI cancers the Vorbipiprant (CR6086) RDE obtained in the Main Study. 27 patients are predicted. No control arm was included, as the target patient population of this study consists of patients in whom the overall survival is less than 6 months and treatment options are very limited and often poorly tolerated, making unlikely that the study results can be significantly biased.

Conditions

  • Refractory Metastatic Colorectal Cancer
  • Solid Tumor
  • Metastatic Microsatellite-stable Colorectal Cancer
  • Mismatch Repair Protein Proficient
  • Metastatic GI Cancers
  • Gastric Cancer

Interventions

  • CR6086Drug

    oral CR6086, twice a day for 14 days

  • AGEN2034Biological

    AGEN2034 3 mg/Kg iv on D1 of each 14- day cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and Tolerability of CR6086 combined with AGEN2034Time frame: From the time of the first dose up to 24 weeks of treatment
  2. Disease Control rate (DCR)Time frame: up to 24 weeks of treatment
  3. Objective Response Rate (ORR)Time frame: up to 24 weeks of treatment

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Istituto Nazionale dei Tumori

    Milan, Milano, Italy

  • Istituto Oncologico Veneto IRCCS

    Padova, Padova, Italy

  • Azienda Ospedaliero Universitaria Pisana

    Pisa, Pisa, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.